New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 27, 2011
14:07 EDTMRKEarnings Preview: Merck trading up ahead of Q3 earnings
Merck (MRK) is expected to report Q3 earnings before the market open on Friday, October 28 with a conference call scheduled for 8:00 am ET. Analysts are looking for EPS of 91c on revenue of $11.61B. The consensus range is 83c-93c for EPS, and $11.47B-$11.95B for revenue, according to First Call. In Q2, Merck reported in-line EPS and better-than-expected revenue. It also reported sales growth for Singular, Remicade, and Animal Health, while raising the full-year EPS to $3.68-$3.76. In its previous conference call, the company announced plans to reduce the workforce by 12%-13% by 2015. The measure would save the company $3.5B by the end of FY12. To accelerate the goal, the Associated Press reported the company may speed up the layoffs to reach that goal. In the previous quarter, Merck announced positive clinical results for several drugs: Isentress, Delura, Odanacatib, and Gardasil. In fact, the CDC voted to expand the use of Gardasil. Investors will also look for updates on the progress of its new type 2 diabetes treatment Juvisync, which recently received FDA approval. Meanwhile, the company signed various research and colloboration agreements with AbD Serotec, Serum Institute of India, and BGI. The company may also mention its sale of its 50% interest in the Johnson & Johnson-Merck joint venture for $175M. Merck was upgraded to Buy at Jeffries, citing valuation and capital allocation. Barron's also said Merck was attractive for its dividend yield, restructuring savings, and expansion in emerging markets.
News For MRK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 4, 2015
07:20 EDTMRKMerck selloff overdone, says SunTrust
After meeting with four senior Merck executives, SunTrust says that the selloff in the stock over concerns about the company's Januvia franchise are overdone. The firm expects the company's diabetes drugs to generate over $8.5B in revenue in 2020, up from less than $6B currently, through the launch of several new treatments within the next two years. It is upbeat on the outlook for the company's Keytruda cancer treatment and reiterates a $72 price target and Buy rating.
September 2, 2015
08:04 EDTMRKMerck says FDA approves pediatric indication for Emend capsules
Subscribe for More Information
September 1, 2015
09:04 EDTMRKMerck reports new analyses from IMPROVE-IT study with Vytorin
Subscribe for More Information
August 30, 2015
12:33 EDTMRKDividend-rich blue chips look attractive amid market volatility, Barron's says
Subscribe for More Information
August 26, 2015
08:53 EDTMRKMerck management to meet with SunTrust
Subscribe for More Information
August 23, 2015
12:35 EDTMRKBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use